Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience

Figure 1 Consort flow diagram showing inclusion and exclusion of patients in study population. Human epidermal growth factor receptor 2 positive (HER2+) invasive lobular carcinomas was defined as an immunohistochemistry score of 3+ or an immunohistochemistry score of 2+ with a HER2 to chromosome 17 ratio ≥ 2.0 for samples after 1 January 2014 and HER2 to chromosome 17 ratio ≥ 2.2 for samples before 1 January 2014 on fluorescence in situ hybridization testing[4]. ILC: Invasive lobular carcinomas; HER2: Human epidermal growth factor receptor 2; IHC: Immunohistochemistry; FISH: Fluorescence in situ hybridization; HER2+: Human epidermal growth factor receptor 2 positive; HER2-: Human epidermal growth factor receptor 2 negative.

Figure 2 Kaplan–Meier estimates of difference in 5-yr and 10-yr overall survival, breast cancer-specific survival and disease-free survival in all 864 human epidermal growth factor receptor 2 positive and human epidermal growth factor receptor 2 negative invasive lobular carcinomas patients by human epidermal growth factor receptor 2 status. A: Overall survival; B: Breast cancer-specific survival; C: Disease-free survival for human epidermal growth factor receptor 2 positive and human epidermal growth factor receptor 2 negative invasive lobular carcinomas patients. HER2: Human epidermal growth factor receptor 2; HER2+: Human epidermal growth factor receptor 2 positive; HER2-: Human epidermal growth factor receptor 2 negative.

Figure 3 Overall survival of all Invasive lobular carcinomas patients by molecular subtype. Basal: Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) negative; HER2+: ER, PR negative and HER2 positive; Luminal A: ER or PR positive and HER2 negative; Luminal B: ER or PR positive and HER2 positive. HER2+: Human epidermal growth factor receptor 2 positive.